Göm menyn

Publications for Maria Hjorth

Co-author map based on Web of Sciences articles 2007-

Publications mentioned in social media 9 times*

Journal Articles

Christopher Sjöwall, Maria Hjorth and Per Eriksson
  Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases
  Lupus, 2017, 26(12), 1333-1338.
   Fulltext  PDF  

Roland Boij, Jenny Mjosberg, Judit Svensson Arvelund, Maria Hjorth, Göran Berg, Leif Matthiesen, Maria Jenmalm and Jan Ernerudh
  Regulatory T-cell Subpopulations in Severe or Early-onset Preeclampsia
  American Journal of Reproductive Immunology, 2015, 74(4), 368-378.
   Fulltext  PDF  
 Web of Science® Times Cited: 3

Mikael Pihl, Linda Åkerman, Stina Axelsson, Mikael Chéramy, Maria Hjorth, R. Mallone, Johnny Ludvigsson and Rosaura Casas
  Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes
  Clinical and Experimental Immunology, 2013, 172(3), 394-402.
   Fulltext  PDF  
 Web of Science® Times Cited: 7

Stina Axelsson, Maria Hjorth, Johnny Ludvigsson and Rosaura Casas
  Decreased GAD(65) -specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
  Diabetic Medicine, 2012, 29(10), 1272-1278.
   Fulltext  PDF  
 Web of Science® Times Cited: 4

Johnny Ludvigsson, Maria Hjorth, Mikael Chéramy, Stina Axelsson, Mikael Pihl, G Forsander, N-O Nilsson, B-O Samuelsson, T Wood, J Aman, E Ortqvist and Rosaura Casas
  Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
  DIABETOLOGIA, 2011, 54(3), 634-640.
   Fulltext  PDF  
 Web of Science® Times Cited: 40

Maria Hjorth, Stina Axelsson, Anna Ryden, Maria Faresjo, Johnny Ludvigsson and Rosaura Casas
  GAD-alum treatment induces GAD(65)-specific CD4(+)CD25(high)FOXP3(+) cells in type 1 diabetic patients
  CLINICAL IMMUNOLOGY, 2011, 138(1), 117-126.
 Web of Science® Times Cited: 36

Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Åkerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson and Rosaura Casas
  Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
  PLoS ONE, 2011, 6(12), .
   Fulltext  PDF  
 Web of Science® Times Cited: 25

Stina Axelsson, Maria Hjorth, Linda Åkerman, Johnny Ludvigsson and Rosaura Casas
  Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65)
  Diabetes/Metabolism Research Reviews, 2010, 26(7), 559-568.
 Web of Science® Times Cited: 19

Ulf-Henrik Mellqvist, Stig Lenhoff, Hans E. Johnsen, Maria Hjorth, Erik Holmberg, Gunnar Juliusson, Jon Magnus Tangen and Jan Westin
  Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin,
  Cancer, 2008, 112(1), 129-135.
 Web of Science® Times Cited: 27

Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson, Agne Lindh, NO Nilsson, Jan Åman, Eva Örtqvist, Peter Zerhouni and Rosaura Casas
  GAD treatment and insulin secretion in recent-onset type 1 diabetes
  New England Journal of Medicine, 2008, 359(18), 1909-1920.
 Web of Science® Times Cited: 292

Maria Hedman Hjorth, Johnny Ludvigsson and Maria Faresjö
  Nicotinamide reduces high secretion of IFN-γ in high-risk relatives even though it does not prevent type 1 diabetes
  Journal of Interferon and Cytokine Research, 2006, 26(4), 207-213.
 Web of Science® Times Cited: 20

F Wisloff, N Gulbrandsen, Maria Hjorth, S Lenhoff and P Fayers
  Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
  European Journal of Haematology, 2005, 75(4), 293-298.
 Web of Science® Times Cited: 18

Conference Articles

Maria Hjorth, Stina Axelsson, Johnny Ludvigsson and Rosaura Casas
  GAD-alum treatment induces GAD-specific FOXP3+ cells in type 1 diabetic children
  in DIABETOLOGIA, vol 52, 2009.

Rosaura Casas, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl and Johnny Ludvigsson
  Specific immunomodulatory effect of GAD(65) in type 1 diabetics
  in DIABETOLOGIA, vol 52, 2009.

Stina Axelsson, Maria Hjorth, L Akerman, Johnny Ludvigsson and Rosaura Casas
  Treatment with alum-formulated GAD65 in type 1 diabetic children results in early induction of Th2 responses
  in DIABETOLOGIA, vol 52, 2009.

Ph.D. Theses

Maria Hjorth
  Immunological profile and aspects of immunotherapy in type 1 diabetes

  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.


Responsible for this page: Peter Berkesand
Last updated: 2017-02-21